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ABSTRACT
Introduction: Inspiratory muscle training (IMT) has
been applied during pulmonary rehabilitation in
patients with chronic obstructive pulmonary disease
(COPD). However, it remains unclear if the addition of
IMT to a general exercise training programme leads to
additional clinically relevant improvements in patients
with COPD. In this study, we will investigate whether
the addition of IMT to a general exercise training
programme improves 6 min walking distance,
health-related quality of life, daily physical activity and
inspiratory muscle function in patients with COPD with
inspiratory muscle weakness.
Methods and analysis: Patients with COPD (n=170)
with inspiratory muscle weakness (Pi,max <60 cm H2O
or <50%pred) will be recruited to a multicentre
randomised placebo controlled trial of IMT and allocated
into one of the two groups. Patients in both groups will
follow a 3 month general exercise training programme,
in combination with home-based IMT. IMT will be
performed with a recently developed device
(POWERbreathe KH1). This device applies an inspiratory
load that is provided by an electronically controlled valve
(variable flow resistive load). The intervention group
(n=85) will undertake an IMT programme at a high
intensity (≥50% of their Pi,max), whereas the placebo
group (n=85) will undertake IMT at a low training
intensity (≤10% of Pi,max). Total daily IMT time for both
groups will be 21 min (6 cycles of 30 breaths).
Improvement in the 6 min walking distance will be the
primary outcome. Inspiratory muscle function, health-
related quality of life and daily physical activity will be
assessed as secondary outcomes.
Ethics and dissemination: Ethics approval has been
obtained from relevant centre committees and the study
has been registered in a publicly accessible clinical trial
database. The results will be easily interpretable and
should immediately be communicated to healthcare
providers, patients and the general public.
Results: This can be incorporated into evidence-based
treatment recommendations for clinical practice.
ClinicalTrials.gov: NCT01397396.
ARTICLE SUMMARY
Article focus
▪ Inspiratory muscle dysfunction occurs in patients
with chronic obstructive pulmonary disease
(COPD) and is associated with dyspnoea and
decreased exercise capacity.
▪ What are the additional functional and health bene-
fits of adding home-based inspiratory muscle
training (IMT) to a general exercise training pro-
gramme in COPD patients with inspiratory muscle
weakness?
Key messages
▪ This multicentre randomised controlled trial will
investigate and report on the additional improve-
ments in exercise tolerance after adding IMT to a
3 months general exercise training programme.
Inspiratory muscle function, health-related quality
of life and daily physical activity will be assessed
as secondary outcomes.
▪ The study will focus on patients with COPDand
inspiratory muscle weakness defined as Pi,max
<60 cm H2O or <50%pred.
▪ The variable flow resistive training method applies
a specific training stimulus and allows full monitor-
ing of the compliance with the home-based IMT.
Strengths and limitations of this study
▪ In contrast to previous studies, we designed a
large, adequately powered, multicentre randomised
controlled trial to investigate the effects of IMT in
patients with COPD and inspiratory muscle weak-
ness. The results from this study will help to clarify
whether adjunctive IMT leads to greater functional
improvements (exercise capacity, quality of life,
participation in daily activity and symptoms) than
exercise training alone.
▪ The results will be focused on effects in COPD
patients with inspiratory muscle weakness. The
results of this study will therefore primarily be
applicable in COPD patients with inspiratory
muscle weakness.
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BACKGROUND
Chronic obstructive pulmonary disease (COPD) is a
major cause of chronic morbidity and mortality world-
wide.1 2 COPD is characterised by persistent expiratory
ﬂow limitation which is usually progressive.3 Dyspnoea is
the most prominent exercise-limiting symptom of the
disease,4 which leads to chronic avoidance of physical
activities. Consequently, low-physical activity levels con-
tribute to skeletal muscle deconditioning and exercise
capacity reduction, which impact negatively on
health-related quality of life.5 6 Inspiratory muscle dys-
function is another extrapulmonary manifestation, which
is often present in patients with COPD.7 8 It contributes
to hypoxaemia, hypercapnia, dyspnoea and decreased
exercise tolerance.9–11 Pulmonary rehabilitation includ-
ing exercise training, education, nutritional intervention
and psychosocial support is a standard care for patients
with COPD to counteract extrapulmonary disease mani-
festations.6 12 13 Inspiratory muscle training (IMT) has
also been applied frequently and is extensively studied in
recent years in patients with COPD.14 From meta-analyses
of randomised controlled trials (RCTs) in patients with
COPD, it can been concluded that IMT as a stand-alone
therapy improves inspiratory muscle function (strength
and endurance), decreases symptoms of dyspnoea and
improves exercise capacity.14 15 The value of IMT as an
add-on to a general exercise training programme is,
however, still under debate.16–19 While IMT always results
in signiﬁcant improvements in inspiratory muscle func-
tion, its additional effects on more clinically relevant out-
comes (eg, functional exercise capacity and quality of
life) are insufﬁciently supported by scientiﬁc evidence so
far.14 From subgroup analyses in the most recent
meta-analysis, it was concluded that signiﬁcant additional
effects of IMT on more clinically relevant outcomes are
more likely to be found in patients with inspiratory
muscle weakness.12 This was previously deﬁned as a
maximal inspiratory mouth pressure (Pi,max) of less than
60 cm H2O.
14 It has therefore been recommended that
future studies in patients with COPD should focus specif-
ically on patients with more pronounced inspiratory
muscle weakness.14 20 It was recently shown that adjunct-
ive IMT led to signiﬁcantly greater functional improve-
ments in a well-designed RCT in patients with chronic
heart failure selected for inspiratory muscle weakness.21
Comparable RCTs in patients with COPD are so far
lacking.14 We are therefore carrying out a large,
adequately powered, multicentre RCT on the effects of
IMT as an adjunct therapy to a general exercise training
programme in patients with COPD with inspiratory
muscle weakness. Recommendations on the use of IMT
as an adjunct to general exercise training in these
patients in international guidelines are ambiguous.12 The
outcome of this study will therefore have a direct impact
on clinical practice, as the results will clarify whether
adjunctive IMT leads to superior clinically relevant
improvements for patients with COPD. Functional
outcomes of relevance to patients (exercise capacity,
quality of life, participation in daily physical activity
and symptoms) were therefore chosen as the main
outcomes.
One of the hypotheses that links enhanced inspiratory
muscle function to improvements in exercise capacity is
that IMT should allow the respiratory system of patients
with COPD to work more comfortably at high lung
volumes during exercise.22 In the present study, we will use
a recently developed IMT device that applies a variable
resistance provided by an electronically controlled valve
(variable ﬂow resistive load). In contrast to the tradition-
ally applied threshold loading, this variable ﬂow resistive
load is speciﬁcally challenging the inspiratory muscles at
higher lung volumes, and may lead to larger training
effects in patients with COPD who develop dynamic hyper-
inﬂation during exercise. Besides these potentially beneﬁ-
cial characteristics of the applied load, another advantage
of the device is the ability to store home-based training
data for up to 40 sessions. Continuous registrations of pres-
sure and ﬂow at 500 Hz provide data on the external work
of breathing and enable the veriﬁcation of quantity as well
as quality of unsupervised training sessions. The latter is of
particular importance since 85% of the training sessions
during this RCT will be performed by patients at their
homes without supervision.
Aims
This study will examine the effects of adding a well-
controlled, high-intensity IMT programme to a 3-month
general exercise training programme, using a large, mul-
ticentre, randomised controlled design, in patients with
COPD and inspiratory muscle weakness. Outcomes will
be exercise capacity (primary outcome), inspiratory
muscle function, health-related quality of life (HRQL)
and participation in daily physical activity.
Hypotheses
We hypothesise that the addition of IMT to a general
exercise training programme in patients with COPD and
inspiratory muscle weakness will result in superior
improvements exercise capacity, inspiratory muscle func-
tion, HRQL and daily physical activity, compared with
general exercise training alone.
METHODS
Patients
All patients with spirometry-proven COPD who are
referred for outpatient pulmonary rehabilitation will be
screened for inclusion. Only patients with inspiratory
muscle weakness (Pi,max <60 cm H2O or <50% predicted)
will be eligible to participate in the study. Exclusion cri-
teria consist of (1) diagnosed psychiatric or cognitive dis-
orders; (2) progressive neurological or neuromuscular
disorders; (3) severe orthopaedic problems having a
major impact on daily activities and (4) previous inclu-
sion in rehabilitation programme (<1 year).
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Study design
Patients will be informed about the study protocol prior
to the start of the rehabilitation programme. Informed
consent will be obtained at that time. Patients will be
randomised into an intervention and a placebo group.
Group allocation will be performed by simple random-
isation using sealed opaque envelopes in random block
sizes of four and six (order unknown to investigators).23
Both groups will follow a general exercise training pro-
gramme as described previously.24 The intervention group
will receive an additional IMT programme described to
the patients as ‘resistance training’ at high intensity (≥
50% Pi,max), whereas the placebo group will receive an
IMT intervention described to patients as ‘endurance
training’ at a low training intensity (≤10% Pi,max).
Measurements of primary and secondary endpoints
will be undertaken before and after 3 months of
rehabilitation. All tests will be performed by experienced
investigators who are blinded to group allocation. To
ensure consistency between the centres, all assessments
will be performed according to the instructions agreed
upon and described in a manual of procedures and an
instructional video, even if they may differ slightly from
usual local procedures. To further improve the consist-
ency, the ﬁve centres will regularly receive a newsletter
to update them on the progress of the study and to
share eventual technical problems between centres. Staff
from all participating centres will be able to contact the
coordinating centre in Leuven by email or telephone in
case they should have any questions concerning the
study.
To detect a minimally clinically important difference
between groups of 26 m in the 6 min walking distance
(6MWD),25 assuming a SD of the within group differences
in the 6MWD at the end of the intervention period of
60 m in both groups with a degree of certainty (statistical
power) of 80% and a risk for a type 1 error (α) <5%, a
sample size for both groups of 85 patients is needed, given
an anticipated dropout rate of 30%. This study will there-
fore be performed as a multicentre RCT to ensure the
inclusion of 170 patients within a time frame of 2 years.
Besides the lead centre at the University Hospital in
Leuven, Belgium, patients will also be recruited in the
University Hospital Gent, Belgium; Schön Klinik
Berchtesgadener Land, Germany; University Hospital
Nijmegen, the Netherlands; and Laval University Quebec,
Canada. Each of the ﬁve centres is expected to include
between 30 and 40 patients within the 2-year inclusion
period.
In accordance with the Belgian law relating to experi-
ments on humans dated 7 May, 2004, KU/UZ Leuven
shall assume, even without fault, the responsibility of any
damages incurred by a subject which linked directly or
indirectly to participation in the study, and shall there-
fore provide compensation through its insurance pro-
gramme. All collaborating sites will have adequate
insurance coverage for (1) Medical professional and/or
medical malpractice liability, (2) general liability and (3)
other possible damages resulting from the Study at the
institution.
INTERVENTIONS
General exercise training
Patients in both groups will follow a 3-month general
exercise training programme. Patients will perform
cycling, treadmill walking, stair climbing, arm ergometry
and resistance training of arm as well as leg muscles.26
Training frequency will be three sessions per week,
resulting in a total of 36 training sessions. Duration of
the training session will increase from 40–60 min at the
start of the programme to 60–90 min after 3 months.
Patients will perform endurance training or interval
training at moderate to high intensity (initially 60–70%
of maximal workload). The overall training intensity will
be increased gradually during the course of the pro-
gramme using a CR10 Borg Scale rating of 4–6 on dys-
pnoea sensation or leg effort as a means of maintaining
training overload.27 Physiotherapists providing this inter-
vention will be blinded to group allocation of patients.
Inspiratory muscle training programme
Patients will receive either high-intensity IMT (‘strength
training’=intervention group) or low-intensity placebo
IMT (‘endurance training’=placebo group). The train-
ing load in this study will be adjusted according to data
from a previously performed pilot study about a home-
based, high-intensity IMT programme in patients with
COPD with inspiratory muscle weakness.28 Total daily
training time for both groups will be 21 min, consisting
of 6 cycles of 30 breaths (2 cycles, 3 times daily in the
intervention group or 3 cycles, 2 times daily in the
control group). There will be approximately 3.5 min of
resistive breathing during every cycle, each followed
by 1 min of resting. Patients will train 7 days/week, for
12 weeks using the Powerbreathe KH1 device
(POWERbreatheKH1, HaB International Ltd, Southam,
UK). This handheld device applies a variable resistance
provided by an electronically controlled valve (variable
ﬂow resistive load). Loading is maintained at the same
relative intensity throughout the breath, by reducing the
absolute load to accommodate the pressure–volume rela-
tionship of the inspiratory muscles. The application of a
tapered load allows patients to get close to maximal
inspiration, even at high-training intensities (ﬁgure 1).
Figure 1 illustrates a comparison of a single breath
(training at an intensity of 60% Pi,max) using a conven-
tional constant threshold loading device, with that of a
variable ﬂow resistive loading device (POWERbreathe
KH1).28 It is apparent from this ﬁgure that, in contrast
to the threshold loading, the variable ﬂow resistive load
overloads the inspiratory muscles at higher lung
volumes. Since one of the hypotheses that links
enhanced inspiratory muscle function to improvements
in exercise capacity is that IMT may allow the respiratory
system of patients with COPD to work more comfortably
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at high lung volumes during exercise,22 we hypothesise
that this variable ﬂow resistive IMT should be better
suited to reduce inspiratory effort (Pes/Pi,max) during
whole body exercise. Besides these hypothetically beneﬁ-
cial characteristics of the applied load, a further advan-
tage of the electronic leading device is the ability to
store parameters of up to 40 IMT sessions. Continuous
registrations of pressure and ﬂow at 500 Hz provide data
on the external work of breathing and enable us to
control quantity as well as quality of unsupervised train-
ing sessions. This is of special importance since 85% of
the training sessions during this RCT will be performed
by patients at their homes without supervision. The
device stores data on average mean pressure (cm H2O),
average mean power per breath (watt), average peak
ﬂow per breath (L/s) and total work of breathing
during one session of 30 breaths ( joules). Patients will
be instructed to perform fast and forceful inspirations
and will be encouraged to achieve maximal inhalation
and exhalation with every breath. This breathing pattern
will be supported by acoustic signals from the loading
device.
The intervention group will start training at 40% of
their initial Pi,max. Intermediate measurements of Pi,max
will be performed every week. These Pi,max values will be
used to calculate the training load to be implemented
the following week. In other words, the training load in
each week will be increased continuously over time by
adjusting to at least 50% of the Pi,max value recorded in
the previous week. Rates of perceived inspiratory effort
on a modiﬁed CR10 Borg Scale (4–6 of 10) will also be
used to support decisions on training load increments.
The control group will train at an inspiratory load of
10% of their initial Pi,max. This training intensity will not
be changed during the study period. Each week, three
training sessions will be performed under supervision at
the outpatient clinic. During these supervised sessions,
the results of unsupervised sessions will be evaluated
and patients will receive instructions and feedback on
their training efforts. Resting periods will be given as
needed as long as the patients are able to complete the
full volume of training prescribed. Training intensity in
the intervention group will be adapted during these
supervised sessions.
When patients experience acute exacerbations or
respiratory infections, they will temporarily interrupt
their participation in the rehabilitation and IMT pro-
gramme. Based on the guidance from the treating pul-
monologist, they will, however, return to the programme
as quickly as possible. Periods of infections, exacerba-
tions and hospitalisations will be registered and their
stay in the programme will be prolonged in order to
complete 12 weeks of IMT training programme.
Outcome measures
Table 1 provides an overview of the outcome measures
at different time points in the study.
Respiratory muscle force
Maximal voluntary respiratory pressures will be regis-
tered at the mouth to assess respiratory muscle force.
Measurements will be performed from total lung cap-
acity for maximal expiratory pressure (Pe,max) or residual
Table 1 Outcome measurements
Start 3 months
Screen X
Informed consent X
Respiratory muscle strength X X
Inspiratory muscle endurance X X
Maximal exercise capacity X X
Endurance exercise capacity X X
Six-minute walking distance X X
Daily physical activity (7 days) X X
Pulmonary function X X
Quadriceps force X X
Handgrip force X X
CRDQ X X
HADS X X
CRDQ, Chronic Respiratory Disease Questionnaire (HRQL);
HADS, Hospital Anxiety and Depression Scale.
Figure 1 Comparison between constant threshold (threshold) and variable resistive inspiratory muscle training (POWERbreathe
KH1).
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volume for maximal inspiratory pressure (Pi,max) using
the technique proposed by Black and Hyatt.29 An elec-
tronic pressure transducer will be used (MicroRPM;
Micromedical, Kent, UK). Assessments will be repeated
at least ﬁve times (30 s recovery between attempts), and
should be continued until at least good reproducibility
has been achieved from the three best measurements
(within 10 cm H2O difference among measurements).
Reference values published by Rochester and Arora30
will be used to deﬁne normal respiratory muscle force.
Inspiratory muscle endurance
To measure inspiratory muscle endurance, patients will
be asked to breathe against a submaximal inspiratory
load provided by the ﬂow resistive loading device
(POWERbreathe KH1), until task failure. The inspira-
tory load that will be selected (typically between 50%
and 60% of the Pi,max) will typically allow patients to
continue breathing against the resistance for 3–7 min.
Breathing instructions for patients will be the same as
during the training sessions. Number of breaths, average
duty cycle (inspiratory time as a fraction of the total
respiratory cycle duration), average mean load, average
mean power and total external inspiratory work will be
recorded during the test by the handheld loading
device. We have recently performed a validation of the
parameters that are recorded during this test and found
excellent agreement between the handheld loading
device and measurements performed with external,
laboratory measurement equipment.31 After 12 weeks of
IMT, the endurance test will be repeated using an identi-
cal load. Improvements in endurance time and breath-
ing parameters will be recorded.
Maximal exercise capacity (incremental exercise test)
Maximal exercise capacity will be assessed by a maximal
incremental cycle exercise test (Ergometrics 900,
Ergoline, Bitz, Germany). After a 2 min resting period and
3 min of unloaded cycling, patients will start cycling at a
load of 20 w. Load will then be increased by 10 w/min and
patients will cycle until symptom limitation. Oxygen
uptake, carbon dioxide output and ventilation will be mea-
sured breath by breath (Vmax series, SensorMedics,
Anaheim, California, USA). Heart rate and oxygen satur-
ation will be recorded continuously. Maximal oxygen
uptake will be compared with normal values.32 The per-
ception of dyspnoea and leg effort will be quantiﬁed at
2 min intervals during exercise and at the end of the test
using the modiﬁed Borg scale.27 The development of
dynamic hyperinﬂation during the exercise test will be
assessed by recording the changes in end-expiratory lung
volumes. Patients will be instructed to perform maximal
inspiratory manoeuvers after a normal expiration during
resting breathing and at the end of each level of exercise.
Assuming a constant total lung capacity, a decrease in
inspiratory capacity will indicate an increase in the
end-expiratory lung volume, which indicates the degree of
dynamic hyperinﬂation.33 Tidal volume (VT), inspiratory
time (TI), total time of the respiratory cycle (TTOT) and
respiratory frequency (fR) will be assessed. The TI/TTOT
(duty cycle) represents the proportion of the breath
during which the inspiratory muscles are contracting.
Endurance exercise capacity (constant work rate test)
A constant power output cycle test until symptom limita-
tion will be performed at 80% of the maximal power
output (in Watts) that was reached during the initial
incremental exercise test (Ergometrics 900, Ergoline,
Bitz, Germany). Oxygen uptake, carbon dioxide output
and minute ventilation will be measured breath by breath
(Vmax series, ). Breathing pattern and dynamic hyperin-
ﬂation will be monitored as described previously for the
incremental cardiopulmonary exercise test. Heart rate
and oxygen saturation will be monitored continuously.
The perception of dyspnoea and leg effort will be quanti-
ﬁed at 2 min intervals during exercise and at the end of
the test using the modiﬁed CR10 Borg scale.27
Six-minute walking distance
Functional exercise performance will be measured using
a 6 min walking test in a 50 m corridor. Standardised
encouragement will be provided.34 The best of the two
tests separated by recovery time of 30 min will be used
and related to reference values.35 Oxygen saturation,
heart rate and symptoms of leg effort and dyspnoea will
be recorded before and after the test.
Physical activity monitoring
Measurements will be performed with an accelerometer-
based activity monitor (DynaPort Minimod, McRoberts
BV, The Hague, The Netherlands). The Minimod is a
small (64×62×13 mm) and lightweight device (68 g,
including batteries) that contains a three-axial piezocapa-
citive sensor measuring at high time-resolution (100 Hz).
Analysis of raw data allows for the classiﬁcation of inten-
sity, duration and frequency of movement. Different pos-
tures and walking are identiﬁed and energy expenditure
is estimated. The Minimod has been validated in patients
with COPD.36 Assessments will be undertaken on seven
consecutive days during waking hours.
Pulmonary function
Spirometry and whole body plethysmography will be per-
formed according to the European Respiratory Society
guidelines for pulmonary function testing (Vmax
Autobox, Sensor Medics, Bilthoven, The Netherlands).37
Diffusing capacity for carbon monoxide will be mea-
sured by the single breath method (Sensor Medics 6200,
Bilthoven, The Netherlands).38
Peripheral muscle force
Isometric quadriceps force will be quantiﬁed using a
Cybex Norm Dynamometer (Cybex Norm, Enraf Nonius,
Delft, The Netherlands). Peak extension torque will be
measured at 60° of knee ﬂexion. At least three measure-
ments will be obtained and the highest reproducible
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value (within 11%) will be taken into analysis. Reference
values have been developed in our laboratory.39
Isometric hand grip force will be measured using a
hydraulic hand grip dynamometer ( Jamar Preston,
Jackson, Michigan). Peak force will be assessed with the
elbow ﬁxed to the rib cage and ﬂexed 90° and with the
wrist in neutral position. At least three measurements
will be obtained and the highest reproducible value will
be taken into analysis and related to reference values.26
Health-related quality of life
The Chronic Respiratory Disease Questionnaire
(CRDQ) will be used to assess HRQL.40 This 20-item
questionnaire scores quality of life in four domains (dys-
pnoea, mastery, emotional functioning and fatigue) and
has been validated in the Dutch, German and French
language.41–43 The total score can range from 20 to 140
with higher scores indicating better quality of life.
Anxiety and depression
The Hospital Anxiety and Depression Scale (HADS) will
be used to assess emotional distress.44 The HADS con-
sists of 14 items and has separate scores for anxiety (7
items) and depression (7 items). A score of 11 or
greater on either of the subscales suggests clinically sig-
niﬁcant symptoms of anxiety or depression.
Statistical analysis
Differences in primary and secondary outcomes
between groups after 3 months of intervention will be
compared adjusting for baseline differences using ana-
lysis of covariance.45 An ‘intention-to-treat’ as well as a
‘per-protocol’ analysis will be carried out to compare
outcomes between groups.
ETHICS AND DISSEMINATION
The results from the RCT of IMT will be submitted for
publication.
DISCUSSION
This large, adequately powered, multicentre RCT will
investigate the effects of IMT as an adjunct to a general
exercise training programme. Outcomes will be exercise
capacity (primary outcome), HRQL and participation in
daily physical activity in the selected patients with COPD
who have pronounced inspiratory muscle weakness. The
IMT in this RCT will be performed using the variable
ﬂow resistive loading device described previously
(POWERbreatheKH1, and validated.31 Besides the hypo-
thetically beneﬁcial characteristics of the applied load
described above, a further advantage of this device is the
ability to store training parameters of up to 40 sessions.
Continuous recording of pressure and ﬂow enables us to
monitor the quantity as well as quality of unsupervised
training sessions. The latter is of special importance,
since 85% of IMT sessions will be undertaken by patients
in their homes, without supervision.
We anticipate that the outcomes of this study will be of
direct relevance to clinical practice. The results of this
study should therefore be incorporated immediately into
evidence-based treatment recommendations for clinical
practice. During the communication of these recom-
mendations, it will be of special importance to stress that
the results obtained in this RCT will be limited to the
selected group of patients with COPD, that is, those with
inspiratory muscle weakness.
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